Loading clinical trials...
Loading clinical trials...
A Phase Ib/IIb, Open-label, Multi-center, Study of Oral Panobinostat (LBH589) Administered With 5-Azacitidine (in Adult Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML).
Conditions
Interventions
Panobinostat (LBH589)
5-Azacytidine
Locations
38
United States
Georgia Health Sciences University Dept. of MCG
Augusta, Georgia, United States
Goshen Center for Cancer Care IU Cancer Center
Indianapolis, Indiana, United States
University of Kansas Hospital and Medical Center SC - Univ KS
Kansas City, Kansas, United States
Dana Farber Cancer Institute Beth Israel Deaconess Med Ctr
Boston, Massachusetts, United States
Memorial Sloan Kettering Sloan Kettering 2
New York, New York, United States
Cleveland Clinic Foundation Cleve Clinic
Cleveland, Ohio, United States
Start Date
December 2, 2009
Primary Completion Date
April 29, 2019
Completion Date
April 29, 2019
Last Updated
August 4, 2020
NCT06303193
NCT05564390
NCT03050268
NCT07320235
NCT06847867
NCT06782542
Lead Sponsor
Novartis Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions